Skip to content
Study details
Enrolling now

Dose Range Finding Trial for Tozorakimab in Adults With Uncontrolled Asthma

AstraZeneca
NCT IDNCT06932263ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

540

Study length

about 3 years

Ages

18–75

Locations

51 sites in CA, DE, FL +22

About this study

This trial is testing different doses of tozorakimab, a medication given by injection, in adults with uncontrolled asthma who are already taking medium-to-high doses of inhaled corticosteroids. The goal is to see if these doses are effective and safe.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take Tozorakimab
PhasePhase 2
DrugTozorakimab

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

monoclonal antibody

Endpoints

Secondary: Change from baseline in post-bronchodilator FEV1, Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1), Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6), Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ12+)

Body systems

Respiratory